SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The disclosure centers on the appointment of Paul Cappuccio as Chief Legal Officer and Corporate Secretary, a named executive officer role. While Benjamin Lee's departure is mentioned, the principal action disclosed is the incoming appointment of Cappuccio to fill the CLO position. The CLO is a material executive role responsible for legal and governance functions, making this appointment material to investors.
View raw filing on EDGAR →Shane Harrison was appointed as Senior Vice President and Chief Financial Officer of Resideo, effective September 1, 2026, with compensation arrangements including a $550,000 base salary, $2,000,000 initial equity award, and $400,000 sign-on bonus.
View raw filing on EDGAR →Joseph A. Alkire is appointed to the role of President and Chief Financial Officer, a material promotion from his prior position as Executive Vice President, CFO and Global Head of Operations. While the disclosure also includes compensatory arrangements (base salary of $900,000, 120% bonus target, and $2.6M long-term incentive award), the principal disclosed action is the appointment to a new executive role. The appointment of a President is material to investors as it signals a significant change in the Company's leadership structure.
View raw filing on EDGAR →Effective August 7, 2026, Becky Fallon, Sean Michael Deegan, and Daniel M. McCabe were appointed as members of the board of directors in connection with the effectiveness of the Company's Registration Statement, with specified committee assignments and qualifications as independent directors and audit committee financial expert.
View raw filing on EDGAR →Pedro Abreu is transitioning from Vice President and Chief Strategy Officer to President, Power Systems, effective September 1, 2026, representing a promotion to a senior operational leadership role. Daniel Griffin is also appointed as President, Aftermarket Solutions. While this involves role changes within the executive team, the principal disclosed action centers on appointments to significant president-level positions overseeing major reportable segments, making exec_appointment the most salient classification.
View raw filing on EDGAR →Kelly Youngblood was appointed as Executive Vice President and Chief Financial Officer effective August 12, 2026, replacing Gregory A. Izenstark. The appointment includes a base salary of $680,000, a bonus target of 85%, a long-term incentive target of 225%, and a $2.03 million RSU grant.
View raw filing on EDGAR →Todd Kelsey was appointed to Littelfuse's Board of Directors effective August 6, 2026, and also appointed to the Compensation Committee. His appointment brings extensive global experience, technology and manufacturing expertise, and public company board experience to the company's governance and strategic direction.
View raw filing on EDGAR →ClearSign Technologies appointed Larry M. Saddler to its Board of Directors effective August 6, 2026, to fill a vacant directorship. Saddler is a retired ExxonMobil executive with 40+ years of industry experience in heat transfer and emissions reduction technology. The appointment includes annual cash compensation of $60,000 and stock option grants of $40,000, plus make-whole payments for covered RSUs.
View raw filing on EDGAR →The press release announces the appointment of J. Michael Rolland to Intermap's Board of Directors. This is a clear executive/governance appointment disclosing a person taking a board role. Rolland brings significant infrastructure financing experience and his appointment is explicitly framed as supporting the company's capital expansion strategy, making it material to investors assessing the company's leadership and strategic direction.
View raw filing on EDGAR →Aura Biosciences appointed Susan Abu-Absi as Chief Operating Officer effective August 10, 2026, with compensation terms including $520,000 base salary, 45% bonus target, and approximately 400,000 shares in equity awards (60% options, 40% RSUs). The company also appointed Erica Kratz as Chief Regulatory Officer and Julie Person as Chief People Officer.
View raw filing on EDGAR →ManpowerGroup appointed John B. Gibson, Jr., President and CEO of Paychex, to its Board of Directors effective September 1, 2026. The disclosure centers on the appointment of a director to the board and his committee assignment, with the board size increasing from ten to eleven directors. This is a clear executive appointment event under Item 5.02, material to investors as it affects board composition and governance.
View raw filing on EDGAR →Barry C. McCarthy, President and CEO of Deluxe Corporation, was appointed as a new director to Radian Group Inc.'s Board of Directors, increasing the Board size from eleven to twelve members. McCarthy brings nearly four decades of leadership experience in payments, financial services, and technology.
View raw filing on EDGAR →Elena Ridloff was appointed to the Board of Directors effective August 6, 2026, bringing 20+ years of biopharmaceutical leadership experience in finance, capital markets, and corporate development to strengthen the board's expertise as the company approaches pivotal Phase 3 readout. Dr. Daniel Vitt resigned from the board and his employment was terminated pursuant to a separation agreement.
View raw filing on EDGAR →PubMatic announced the appointment of Megan Ramm as Global Chief Revenue Officer, effective August 10, 2026. The disclosure centers on her taking a senior executive role leading global revenue strategy across all regions. While the filing also details her compensation package (base salary of $500,000, performance bonus target of $500,000, and equity awards totaling $5.75 million), the principal disclosed action is the appointment itself, not the compensation arrangement. This is material as it involves a key C-suite leadership position at the company.
View raw filing on EDGAR →The filing discloses the appointment of V. Ray Rivers to the Board of Directors effective August 10, 2026, and his concurrent appointment to the Audit Committee and Compensation Committee. The Item 5.02 disclosure emphasizes his extensive capital markets and financial services background, his independent director status under Nasdaq standards, and his compensation package ($25,000 annual retainer plus committee fees and equity grant). This is a clear director appointment that strengthens board expertise and is material to investors assessing governance quality.
View raw filing on EDGAR →The filing discloses the appointment of Vikas Choudhary as a director of Everspin Technologies, effective August 9, 2026. While the disclosure also includes compensatory arrangements (RSU award of $250,000 and annual cash retainer of $55,000), the principal action is the director appointment itself. The detailed biographical information and board service terms confirm this is a material executive appointment that would affect investor assessment of the company's governance and leadership.
View raw filing on EDGAR →Southwest Airlines appointed two new directors to its Board: Varun Krishna (CEO of Rocket Companies and interim CEO of Redfin) and Jason T. Liberty (Chair and CEO of Royal Caribbean Cruises Ltd.), effective immediately, increasing the Board size to thirteen members.
View raw filing on EDGAR →The filing discloses the appointment of Paul Hoelting to Werner Enterprises' Board of Directors to fill a Class I directorship vacancy, effective August 7, 2026. While the disclosure includes standard director compensation details (cash retainer, restricted stock award, committee fees), the principal action is the appointment itself. This is a material governance event affecting the composition of the board at a publicly traded transportation company with $3 billion in annual revenues.
View raw filing on EDGAR →The news release announces the appointment of Mark E. Smith as Chairman of the Board, effective immediately. While the release also discusses the 2026 site program at the Casino project, the principal disclosed action is a leadership change—a director since November 2025 being elevated to Chairman, succeeding Raymond Threlkeld. This is a material governance event affecting the registrant's board leadership and control structure.
View raw filing on EDGAR →The filing discloses the appointment of Scott Kotarba to the Board of Directors effective August 10, 2026, filling a vacancy created by Ian Wendler's retirement on July 31, 2026. While both a departure and an appointment occur, the principal disclosed action centers on the appointment of a new director. The filing details Mr. Kotarba's background, compensation ($12,000 annually plus 25 restricted shares per quarter), and his prior consulting relationship with the company. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →The 6-K announces three executive leadership changes effective August 10, 2026: appointment of Daniel Mamadou-Blanco to the board of directors and Investment Committee, appointment of Steve Zhang as Co-Chief Financial Officer, and promotion of Yi Bao to Chief Operating Officer. While the filing also discloses Bo Shen's departure from the board, the principal disclosed actions are the three appointments/promotions of new or elevated leadership roles. These are material governance events affecting the registrant's leadership structure and strategic direction.
View raw filing on EDGAR →Agomab Therapeutics announced the proposed appointments of Marino Garcia and Dr. Naimish Patel as non-executive members of the Board of Directors, to be submitted for shareholder approval at a Special General Meeting on September 11, 2026. Both candidates bring significant industry experience in biotechnology leadership and clinical development, directly relevant to the company's strategic direction.
View raw filing on EDGAR →The filing discloses the appointment of Qunxue Yin as Chief Executive Officer and Chairman of the Board effective immediately on August 8, 2026, following the resignation of Jialuan Ma on August 6, 2026. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new CEO and Chairman with detailed biographical information and qualifications. This is material as it represents a change in the Company's principal executive officer and board leadership.
View raw filing on EDGAR →The letter discloses multiple executive leadership transitions effective December 31, 2026 and August 3, 2026: Vivek Bantwal becomes sole Chief Executive Officer of the Goldman Sachs BDC complex; Justin Betzen becomes Co-President and Co-Chief Operating Officer alongside Tucker Greene; and Greg Watts and Steven Budig are elevated to co-heads of Americas Direct Lending. While David Miller's departure as Co-CEO is also mentioned, the primary focus and substance of the disclosure centers on the appointments and promotions of these executives into expanded roles, making exec_appointment the most salient classification.
View raw filing on EDGAR →Jeff D. Martinez was appointed as Senior Vice President, Utility Operations effective October 1, 2026, with a salary increase from $380,000 to $500,000, joining the Management Committee. James H. Jeffries IV was elected to the Board of Directors effective September 1, 2026. John S. McDill announced his retirement as Senior Vice President, Utility Operations in early 2027.
View raw filing on EDGAR →Natuzzi announces it has "signed a commitment letter with a candidate for the role of Chief Executive Officer." While the appointment is not yet finalized (it is a commitment letter with a candidate, not a completed appointment), the disclosure of a CEO succession process is material to investors assessing leadership continuity and strategic direction. The company emphasizes the candidate's "extensive international experience" and belief that his profile will support "ongoing restructuring process and long-term strategic development," indicating this is a significant governance event. The language suggests an imminent appointment rather than a speculative search.
View raw filing on EDGAR →The filing discloses the appointment of two new directors, David Benson and David Cush, to SAIC's Board effective August 20, 2026, with the Board size increasing from ten to twelve members. Both appointees bring substantial executive and board experience (Benson from Fannie Mae and Merrill Lynch; Cush from Virgin America and American Airlines), and will serve on key committees including the Audit Committee. This is a material governance event affecting board composition and oversight structure.
View raw filing on EDGAR →The filing discloses the appointment of Kashif Rashid as Chief Legal Officer and Corporate Secretary, effective August 10, 2026, following the Board's decision on August 6, 2026. While the section also includes Jeremy Hayden's departure as Chief Legal Officer, the principal disclosed action centers on the appointment of a new executive officer to a key leadership role. The appointment includes detailed employment terms (base salary of $450,000, 50% bonus target, severance provisions) and an RSU award of $1,400,000, making this a material executive appointment that would affect investor assessment of the company's leadership and governance.
View raw filing on EDGAR →The disclosure centers on the Board's appointment of Alan Musso as principal accounting officer effective August 7, 2026, following Greg Tourangeau's departure from that role. While both a departure and an appointment occur, the principal action disclosed is the appointment of Musso to the principal accounting officer position. The appointment of a principal accounting officer is a material governance event affecting the registrant's financial reporting oversight.
View raw filing on EDGAR →Annexon appointed Mark S. Blumenkranz, M.D., M.M.S. to its board of directors effective August 10, 2026, and assigned him to the Audit Committee and Science and Technology Committee. Dr. Blumenkranz brings significant expertise in retinal disease and biotechnology leadership to support the company's late-stage clinical programs.
View raw filing on EDGAR →The filing discloses the appointment of S. Wade Sheek as Chief Legal Officer and Corporate Secretary, effective August 17, 2026, replacing Nathaniel A. Vitan. While the section also mentions Vitan's transition to a senior advisor role, the principal disclosed action is the appointment of a named executive officer to a C-suite position. This is material as it affects the registrant's senior leadership and governance structure.
View raw filing on EDGAR →The 6-K announces the nomination of Ms. Janet DiFiore to the Board of Directors to fill the seat vacated by Mr. Gurpal Grewal, who determined not to stand for re-election. Although the appointment is subject to shareholder approval at the upcoming annual meeting, the principal disclosed action is the nomination of a director candidate with substantial public-sector credentials (former Chief Judge of New York Court of Appeals). This is a material governance event affecting board composition.
View raw filing on EDGAR →Dr. Charles S. Fuchs was appointed President, Research & Development of Erasca, Inc., effective August 10, 2026. This is a material executive appointment of a senior officer with significant oncology and biopharmaceutical development experience, including prior roles at Roche/Genentech and Yale Cancer Center. The appointment includes substantial compensation (base salary $570,000, 45% bonus target, and 1.3 million stock options), making it material to investors' assessment of the company's leadership and strategic direction.
View raw filing on EDGAR →The filing discloses the appointment of Eric Williams as Executive Vice President of Engineering, effective August 31, 2026. While the disclosure also includes compensatory arrangements (base salary of $400,000 and 40% target bonus), the principal action is the appointment of a named executive officer with significant prior experience (three decades of advanced reactor engineering leadership from TerraPower). The appointment of a senior executive to a newly-filled or newly-created role is material to investors assessing the company's leadership and operational capacity.
View raw filing on EDGAR →The filing discloses the appointment of Kenji Konishi as Head of Magnet Engineering Production, a senior operational leadership role. The press release emphasizes his decades of experience scaling rare earth magnet production and notes he is joining with "a team of senior engineers," positioning this as a material executive appointment critical to the company's expansion toward 10,000 metric tons of annual capacity by November 2026 and DFARS compliance by January 1, 2027.
View raw filing on EDGAR →The 6-K announces the appointment of Daniel Brau as Chief Quantum Officer of SEALSQ effective August 4, 2026, following the Company's acquisition of Miraex SA. The disclosure includes detailed biographical information, his prior role as CEO of the acquired company, and his new responsibilities overseeing the quantum technology portfolio and strategic partnerships. This is a material executive appointment tied to a significant acquisition integration.
View raw filing on EDGAR →The press release announces the appointment of André Cazotto as Chief Financial Officer of PicPay, effective immediately, succeeding Rodrigo Couto who transitions to Special Advisor. This is a material executive appointment at the C-suite level (CFO) at a recently IPO'd company (January 2026), and the disclosure explicitly details Cazotto's qualifications and his expanded responsibilities overseeing financial operations, investor relations, strategy, and M&A.
View raw filing on EDGAR →Four directors—Andrew Rechtschaffen, Karen Martin, Paul Stoyan, and Harry Brandler—were appointed to the board in connection with the IPO on August 6, 2026, with assignments to specific board committees.
View raw filing on EDGAR →The filing discloses the appointment of Wesley Batista Filho as Global CEO effective January 2027, alongside the concurrent departure of Gilberto Tomazoni. While both events occur, the principal action announced is Batista Filho's appointment to the top executive role. The filing emphasizes his appointment and career trajectory at JBS, making this the salient event, though the concurrent CEO transition is also material.
View raw filing on EDGAR →The disclosure centers on the Board's appointment of Anthony W. Boor as a new Class A director on August 5, 2026. Although the filing also describes his existing role as Executive Vice President of Corporate Development and Strategy and references his retention agreement with compensation details, the principal disclosed action is his election to the Board. This is a material governance event affecting the composition of the registrant's board of directors.
View raw filing on EDGAR →Peter G. Eames was appointed as president and chief executive officer and elected to the Board of Directors, succeeding Daniel A. Baker who retired from the CEO role. Carolyn W. Valentine was also elected to the Board.
View raw filing on EDGAR →The filing discloses a comprehensive executive leadership transition effective August 6, 2026, with the departure of two senior officers (LOKE WENG CHAN and Dr. JIMMY LOKE) and the appointment of five new executives including a new President and CEO (CHAI KOK LEONG), CFO and Board Chairman (GILBERT LOKE), CMO (LOUIS TANG), Chief Strategy Officer (Dr. JIMMY LOKE in a new role), and CTO (ZHENG XIANG). While both departures and appointments occur, the filing's primary focus and structure emphasize the appointment of new leadership across all major executive functions, making exec_appointment the most salient classification.
View raw filing on EDGAR →The filing discloses both a departure (Martin Shen's resignation as CEO and Director on August 4, 2026) and an appointment (Jolie Kahn's appointment as CEO and Director effective the same date). While both events occurred, the principal disclosed action centers on the appointment of a new CEO with extensive qualifications in corporate finance, public company leadership, and securities law. The detailed biographical information and forward-looking tone emphasize the appointment as the material event driving the disclosure.
View raw filing on EDGAR →The filing discloses the appointment of Christine Chambers as Chief Financial Officer of MicroVision, Inc., effective August 27, 2026. Item 5.02 explicitly covers this appointment, and the prose centers on her appointment to a principal officer role. While compensatory arrangements are also disclosed, the primary disclosed action is the appointment itself, making exec_appointment the most salient classification. This is material as CFO appointments affect investor assessment of financial leadership and governance.
View raw filing on EDGAR →The filing discloses the appointment of Mr. Diego Cesar Santilli as a Director representing Class A Shares, appointed by the Argentine National State (the Class A shareholder) and acknowledged by the Board on August 10, 2026. This is a clear executive/board appointment event. The appointment is material as it represents a change in board composition at a major oil company where the state is a significant shareholder.
View raw filing on EDGAR →Innate Pharma appointed Markus Jensen as Chief Medical Officer effective September 1, 2026, succeeding Sonia Quaratino. The appointment is material as it involves a named executive officer role critical to clinical and regulatory execution during a pivotal phase of the company's development.
View raw filing on EDGAR →Chris Rogers was appointed to the newly created position of President and Chief Strategy Officer effective July 27, 2026, with expanded strategic and operational oversight across the enterprise, including corporate strategy, business development, M&A, and investor relations. This represents a material senior leadership appointment at the recently IPO'd company (June 2026), expanding his prior Chief Growth Officer role.
View raw filing on EDGAR →Duolingo appointed Sallie Krawcheck as a Class I director and member of the Audit, Risk and Compliance Committee, effective August 10, 2026. Krawcheck brings extensive financial and operational experience from her prior roles as CFO of Citigroup, CEO of Merrill Lynch, and founder of Ellevest.
View raw filing on EDGAR →The Board appointed Angie O'Leary as Executive Vice President and Chief Financial Officer, effective August 6, 2026, following her service as Interim CFO since March 2026. Her compensation package includes a base salary of $425,000, target bonus of 65%, and long-term incentive opportunity of 120%+, along with severance provisions.
View raw filing on EDGAR →The Board appointed Erik J. Bello as Vice President and Chief Accounting Officer, effective August 31, 2026, with responsibility as the Company's principal accounting officer. While the disclosure includes compensation details (base salary of $380,000, sign-on bonus, equity awards), the principal disclosed action is the appointment of a named executive to a material officer role. The compensation is ancillary to the appointment itself.
View raw filing on EDGAR →